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Abstract
Background and aims. Recognized prognostic factors for resected pancreatic ductal adenocarcinoma (PDAC) include
tumour size, differentiation, resection margin involvement and lymph node metastases. A further prognostic factor of less
certain significance is lymphocyte count. The aim of this study was to investigate whether preoperative lymphocyte count is
a prognostic indicator in patients with PDAC. Material and methods. Patients who had undergone a potentially curative
pancreaticoduodenectomy (PD) for PDAC between 1998 and 2005 were analysed. Standard prognostic factors,
preoperative lymphocyte count, preoperative neutrophil count and survival data were collected. Results. Of the 44 patients
studied, univariate analysis identified predictors of a poor survival as lymph node status (node positive (ve) 10.3 [5.4
20.9] months versus node negative (ve) 14.2 [10.931.4] months; p0.038), posterior resection margin invasion (margin
ve 7.0 [5.115.0] months versus margin ve 13.1 [10.028.3] months; p0.025) and lymphocyte count below the
reference range (B1.5109/litre 8.8 [7.013.1] months versus ]1.5109/litre 14.3 [7.028.3] months; p0.029). Low
preoperative lymphocyte count (p0.027) and posterior margin invasion (p0.023) retained significance on multivariate
analysis. Preoperative neutrophil to lymphocyte ratio was not a significant prognostic factor. Conclusion. Preoperative
lymphocyte count is a significant prognostic factor in patients with PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a dis-
ease with a poor prognosis and a median survival of
1218 months when resected with curative intent [1
11]. However, there are few actual 5-year survivors,
with even fewer patients truly cured of the disease
[10]. In a study of over 100,000 patients diagnosed
with pancreatic cancer, only 9% were eligible for
potentially curative resection [12]. The majority of
pancreatic cancers are in the head of the gland, i.e.
necessitating pancreaticoduodenectomy (PD). This is
a major operative intervention normally associated
with a high mortality and morbidity, although large
series with no in-hospital or 30-day mortality have
been reported from specialist centers [13].
Well-established prognostic factors include tumour
size, differentiation, resection margin involvement and
lymph node metastases [1,3,811,14,15]. A further
prognostic factor of less certain significance is lympho-
cyte count, which has previously been shown to be
associated with shorter survival [16,17]. Lymphocyto-
penia has been reported in various cancers, but is
particularly marked in patients with PDAC [1820]. It
has been suggested that a low lymphocyte count
indicates a state of immunosuppression, which is
thought to be present at a systemic [21] and local level
in patients with PDAC [2125]. In these studies, quan-
titative and functional deficiencies of lymphocytes
were identified and it is therefore hypothesized that
this may contribute to the poor prognosis of PDAC
with a reduced host response against tumour cells.
The aim of this study was to investigate whether
preoperative lymphocyte count is a prognostic indi-
cator in patients with PDAC.
Methods
Patients who had undergone a potentially curative PD
for pancreatic cancer between 1998 and 2005 were
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identified. Only those with PDAC confirmed on
pathological examination were included in the analy-
sis. Data were collected from a prospectively collected
database and supplemented by retrospective case note
review and cross-referenced against the laboratory
computerized results system.
Standard histopathological prognostic factors in-
cluding lymph node involvement, resection margin
involvement, tumour size and differentiation were
collected to ensure lymphocyte counts were indepen-
dent of these. Demographic data including age at
operation, sex, and survival (date of operation to date
of death) were collected. In addition, lymphocyte and
neutrophil counts on routine blood tests taken in the
week prior to surgery were recorded. The median
lymphocyte and neutrophil counts were calculated.
Patients were grouped according to whether the
lymphocyte count was above or below the lower limit
of the normal reference range (1.5109/litre).
Furthermore, the preoperative neutrophil to lympho-
cyte count ratio was calculated. Patients were grouped
according to whether their neutrophil to lymphocyte
ratio (NLR) was less than or greater than 5.
Statview version 5.0.1 software was used for statis-
tical analysis. Continuous data are presented as
median (interquartile range). Actual survival was
assessed by the Kaplan-Meier method and compar-
isons were made using the log rank test. Multivariate
analysis was performed to determine the significance
of prognostic variables using the Cox proportional
hazards method. A p-value of B0.05 was considered
significant.
Results
Forty-four patients with a median age of 65 (5971)
years were analysed. The median survival was 11.7
(6.417.0) months. Potential prognostic factors are
given in Table I. On univariate analysis, lymph node
status (node positive (ve) 10.3 [5.420.9] months
versus node negative (ve) 14.2 [10.931.4] months;
p0.038), posterior resection margin involvement
(margin ve 7.0 [5.115.0] months versus margin
ve 13.1 [10.028.3] months; p0.025) and lym-
phocyte count (B1.5109/litre 8.8 [5.313.3]
months versus ]1.5109/litre 15.0 [10.028.3]
months; p0.0087) were shown to be predictors of
a poor survival. Low lymphocyte count (p0.027)
and posterior margin invasion (p0.023) remained
significant on multivariate analysis (Figures 1 and 2).
Tumour size, resection margin involvement (any
margin), differentiation and preoperative NLR were
found not to be significant prognostic factors.
Discussion
Pancreatic cancer is a disease with a poor prognosis.
Of the prognostic variables analysed, low preoperative
lymphocyte count and posterior resection margin
were found to be significant on multivariate analysis
(Figures 1 and 2).
Although invasion of the posterior resection margin
was identified as a significant prognostic factor,
involvement of the resection margin (any margin)
was not a significant prognostic variable (p0.10).
Residual tumour is often found at the posterior
resection margin with complete resection sometimes
difficult due to the immediate proximity of major
vascular structures. Invasion specifically of the poster-
ior resection margin has previously been identified to
be associated with an adverse prognosis [5,6,14,26].
Preoperative lymphocyte count less than the lower
limit of the reference range (1.5109/litre) was also
found to be a predictor of shorter survival on
multivariate analysis (p0.027). Preoperative lym-
phocyte count has previously been shown to be
predictive of survival in patients with potentially
resectable PDAC [16,17]; however, the numbers of
subjects in these studies were small. The current
study consisted only of patients who underwent
pancreaticoduodenectomy for PDAC (as confirmed
by pathological analysis) representing a very select
Table I. Prognostic factors in patients with PDAC.
Variable n
Median survival (IQR)
(months)
p-value univariate
analysis
p-value multivariate
analysis
Lymph nodes involved ve 34 10.3 (5.420.9) p0.038 p0.20
ve 10 14.2 (10.931.4)
Posterior resection margin ve 16 7.0 (5.115.0) p0.025 p0.023
ve 28 13.1 (10.028.3)
Resection margin ve 21 8.8 (5.415.0) p0.10 
ve 23 14.3 (9.928.3)
Tumour size 52 cm 52 cm 6 20.9 (19.931.4) p0.18 
2 cm 38 10.3 (7.019.6)
Poorly differentiated Yes 20 8.7 (5.112.7) p0.44 
No 24 14.8 (8.827.9)
Neutrophil to lymphocyte ratio ]5 Yes 4 8.9 (5.313.3) p0.16 
No 40 10.5 (7.121.2)
Lymphocyte count B1.5109/litre Yes 20 8.8 (5.313.3) p0.0087 p0.027
No 24 15.0 (10.028.3)
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group, removing the potentially confounding variable
of tumour type but confirming the previous findings.
Although lymphocyte count was a significant
prognostic factor, the NLR was not. In the present
study, patients were grouped according to whether
their NLR was less than or greater then 5, as
previous studies have shown that a preoperative
NLR of 5 has a prognostic significance in patients
undergoing resection of colorectal cancer and color-
ectal cancer liver metastases [27,28]. In the present
study, only 4 patients had a neutrophil to lympho-
cyte count 5, and therefore the results of the
present study are difficult to interpret with respect to
the prognostic value of the NLR. However, given
that the majority of patients in this study had a
normal neutrophil count, the observed lymphocyto-
penia of patients included in this study is less likely
to be due to biliary sepsis, which would be associated
with an increased neutrophil count and reduced
lymphocyte count [29].
The prognostic value of lymphocyte count in
irresectable PDAC has not been reported in the
litreature. However, leukocytosis has previously been
shown to be associated with poor prognosis in patients
with irresectable PDAC [30]. It was suggested that
this may be explained by the significant morbidity and
mortality associated with cholangitis with which a
high white cell count would be expected.
Lymphocytopenia is present in many types of
cancers and is thought to reflect a generalized state
of depressed immune function [18]. Depressed im-
mune function may influence survival adversely due
to reduced host response to the tumour cells. A study
comparing patients with pancreatic, gastric and color-
ectal carcinoma found that patients with PDAC had
more marked lymphocytopenia preoperatively and
postoperatively [20].
In patients with PDAC, increasing T-stage has been
shown to correlate with decreasing CD3-, CD4- and
CD8- lymphocyte counts [18]. Furthermore, part of
the host defence against PDAC is thought to involve
local tumour infiltration with lymphocytes [2123]. It
has been shown that tumour infiltration with a large
number of CD4 and CD8 lymphocytes in PDAC
is associated with improved prognosis [22].
Immunological tumour escape mechanisms invol-
ving lymphocytes have also been identified in PDAC,
which may potentially adversely influence survival.
The Fas system, which comprises the Fas receptor
and its ligand, Fas ligand (FasL), is a central
mediator of apoptosis under physiological and patho-
logical conditions [31]. Abnormal expression of
functional FasL has been shown to occur in PDAC
cells and is thought to induce apoptosis of tumour
infiltrating lymphocytes which have high expression
of the Fas receptor [24,25]. Impairment of T cell
function is also thought to occur in PDAC due to
high circulating levels of the inhibitory cytokines
interleukin-10 and transforming growth factor-b1/2
with inactivation of these cells being reflected by loss
of the CD3k chain [21]. In the majority of PDAC
specimens, lymphocytes are ‘‘trapped’’ in fibrous
peritumoral tissue and prevented from infiltrating
the cancer, a further possible tumour escape me-
chanism [21].
Another simple blood test, which has been identi-
fied to have prognostic significance in patients with
PDAC, is C-reactive protein (CRP) [3237]. This has
been shown to correlate inversely with survival and
was used in these studies as an index measurement of
the systemic inflammatory response which is thought
to exist in PDAC patients. A raised CRP level has also
been shown to be related to the degree of cancer
cachexia [32,33,38]. Furthermore, encouraging re-
sults have been achieved using combined adjuvant
chemoradiotherapy and immunotherapy with a re-
ported 5-year survival of 55% [39]. Taken together,
these findings suggest that there may be an immuno-
logical basis to this disease.
The well-established prognostic variables in re-
sected PDAC are pathological features, but few
discriminating preoperative variables have been iden-
tified as having prognostic significance in patients with
potentially resectable PDAC. The results of this study
suggest that lymphocyte count may be useful in
determining prognosis in patients with PDAC. This
study also adds to the body of evidence suggesting
that immunological mechanisms may contribute to
the poor prognosis of PDAC. If the results of this
study are borne out in a larger study, preoperative
lymphocyte count could potentially be included in a
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Figure 1. Effect of posterior margin invasion on survival *univariate
analysis.
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Figure 2. Effect of lymphocyte count on survival *univariate
analysis.
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prognostic nomogram for PDAC similar to that
previously constructed by Brennan et al. [11].
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